Cell Society International Hosts its 2nd Annual Clinical Conference in San Diego, CA, to Discuss Clinical Advancements in Adult Stem Cell Therapies and Regenerative Medicine
LA JOLLA, Calif., Jan. 25, 2012 /PRNewswire/ — Interest in adult stem cell therapies and their clinical applicability in treating and helping patients is growing, while accurate information remains difficult to access. Cell Society International, a nonprofit organization, is dedicated to advancing the clinical applications of adult stem cell therapies worldwide through education and the collaboration of world thought leaders.
According to Emerson C. Perin, MD, PhD, Director, Clinical Research for Cardiovascular Medicine and Medical Director, Stem Cell Institute, Texas Heart Institute, Houston, TX and member of the Board of Directors of Cell Society, “We obtained remarkable results from our study in which we injected stem cells derived from the bone marrow of a healthy donor into patients with heart failure. Heart function and exercise capacity improved in some cell-treated patients. Most importantly, cell therapy significantly reduced cardiac adverse events, including death. Three of 15 (20%) control patients died of cardiac causes, whereas only 1 of 45 (2%) cell-treated patients had a cardiac-related death. Despite the small numbers, our findings showed that cell therapy significantly improved cardiac mortality.”
The 2nd Annual Clinical Meeting of Cell Society will be held at the Coronado Island Marriott Resort in San Diego, California on February 17 – 18, 2012. International and national clinical researchers and thought leaders will share current information on adult stem cell applications in a variety of therapeutic categories The two-day conference will offer clinical updates on cell therapies in plastic surgery, wound healing, cardiac disease, stroke, MS, bone healing and cartilage regeneration, to name a few, as well as industry updates from leading developers of cell therapies and medical devices. The second day includes a panel discussion titled The Practice of Medicine and Government Regulation: The Rubicon as well as a session focused on the Future of Stem Cell Therapy in the United States. Leading experts from around the globe will discuss the challenges facing all who are involved in the advancement of regenerative medicine through the use of stem cell therapy. Up to 11.5 CME credits will be available for attendees.
About Cell Society International: Cell Society was formed in May 2010, to serve as an independent source of educational information for all interested in clinically relevant adult stem cell therapy applications. As a nonprofit mutual benefit corporation, Cell Society will utilize the expertise of its industry relationships as well as the cooperation of patients, their physicians and world thought leaders to advance the clinical applications of adult stem cell therapies worldwide. For more information about registration and sponsorship for the 2nd Annual Clinical Meeting please visit http://xmedicacme.com/cell_society or contact info@xMedicaCME.com
SOURCE Cell Society International